HC Wainwright Reaffirms Buy Rating for TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $55.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 59.79% from the company’s current price.

Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. raised their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. The Goldman Sachs Group raised their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, StockNews.com lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. According to MarketBeat, TG Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Trading Up 14.4 %

Shares of NASDAQ:TGTX opened at $34.42 on Tuesday. TG Therapeutics has a 1 year low of $12.93 and a 1 year high of $36.84. The stock’s fifty day moving average price is $30.79 and its 200-day moving average price is $28.24. The company has a market cap of $5.36 billion, a P/E ratio of -344.17 and a beta of 2.30. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. The firm had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. Sell-side analysts expect that TG Therapeutics will post 0.08 earnings per share for the current year.

Insider Activity

In other news, CFO Sean A. Power sold 10,021 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. This trade represents a 1.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.50% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Private Advisor Group LLC boosted its stake in shares of TG Therapeutics by 3.9% in the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock worth $337,000 after acquiring an additional 542 shares during the period. New York State Teachers Retirement System bought a new position in TG Therapeutics in the 3rd quarter worth approximately $1,004,000. Amalgamated Bank boosted its stake in TG Therapeutics by 712.0% in the 3rd quarter. Amalgamated Bank now owns 39,528 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 34,660 shares during the period. Principal Financial Group Inc. grew its holdings in TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after buying an additional 725,371 shares in the last quarter. Finally, Los Angeles Capital Management LLC raised its position in shares of TG Therapeutics by 33.7% during the third quarter. Los Angeles Capital Management LLC now owns 123,401 shares of the biopharmaceutical company’s stock valued at $2,886,000 after buying an additional 31,124 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.